Videos
The role of PCSK9 inhibitors in FH
The low density lipoprotein cholesterol (LDL-C) lowering effects of evolocumab, a new PCSK9 inhibitor, in patients with familial hypercholesterolaemia (FH) are very encouraging, Dr Dirk Blom, University of Cape Town says. This will be very important in countries such as South Africa.
read more »
Looking ahead with PCSK9 Education & Research Forum
Researchers and clinicians are enthusiastically expanding their knowledge of important new discoveries in cholesterol lowering therapies with PCSK9 inhibitors. Co-editor, Professor Henry Ginsberg, looks to the future.
read more »
LDL-C: how low should clinicians aim for?
Trials with monoclonal antibodies – PCSK9 inhibitors – will answer the question of how far should low density lipoprotein cholesterol (LDL-C) be reduced?
read more »
What are the patient priorities for PCSK9 inhibitors?
The low density lipoprotein cholesterol (LDL-C) lowering potency of the new PCSK9 inhibitors, creates exciting opportunities to effectively lower lipids in high risk patients, including those with familial hypercholesterolaemia (FH) for the first time. Professor Henry Ginsberg discusses the clinical potential of these new therapies.
read more »
What are the gaps in knowledge about the PCSK9 inhibitors
Large clinical studies of innovative monoclonal antibodies targeting PCSK9 to significantly reduce low density lipoprotein cholesterol (LDL-C). Professor Evan Stein predicts the therapies will be on the market in 2015.
read more »
ODYSSEY FH and patient unmet needs
Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY…
read more »The role of PCSK9 inhibitors in FH
Monoclonal antibodies targeting PCSK9 have been shown to reduce low density lipoprotein cholesterol (LDL-C) by 30-40% in patients with familial hypercholesterolaemia (FH) who still have LDL receptors. Studies also show that the investigational drug, evolocumab was well tolerated, Dr Dirk Blom said.
read more »
Take home messages from ACC2014
Results of studies presented in 2014, show that PCSK9 inhibitors: 1) very effectively reduce low density lipoprotein cholesterol (LDL-C); and 2) show consistently predictable safety profiles. The positive results of short-term studies are now being reported in longer terms and larger clinical studies, Dr Evan…
read more »
Does PCSK9 inhibition impact atherosclerosis?
Research shows that progression of atherosclerosis – narrowing of the coronaries due to high density lipoprotein cholesterol (HDL-C) – may be reduced if statins are combined with new PCSK9 inhibitors. This could prevent heart attacks according to one of the trialists, Professor Steve Nicholls from…
read more »
Do the PCSK9 inhibitors have pleiotropic effects?
Experimental studies show that significant reductions in low density lipoprotein cholesterol (LDL-C) will significantly reduce inflammation which is important in Atherosclerosis (narrowing of the arteries) says Professor Erik Stroes.
read more »
